v3.25.3
NOTES PAYABLE TO SHAREHOLDER (Tables) - Shareholder [Member]
9 Months Ended
Sep. 30, 2025
Defined Benefit Plan Disclosure [Line Items]  
SCHEDULE OF NOTES PAYABLE TO SHAREHOLDER

Notes payable to shareholders consisted of the following:

     

   September 30,   December 31, 
   2025   2024 
         
December 6, 2021 ($50,000)  $      -   $50,000 
February 11, 2022 ($150,000)   -    150,000 
May 8, 2022 ($550,000)   -    550,000 
May 16, 2022 ($1,100,000)   -    1,100,000 
May 18, 2022 ($450,000)   -    450,000 
June 1, 2022 ($500,000)   -    500,000 
June 30, 2022 ($922,028)   -    922,028 
August 25, 2022 ($290,000)   -    290,000 
November 15, 2022 ($450,000)   -    450,000 
May 16, 2023 ($150,000)   -    150,000 
May 18, 2023 ($50,000)   -    50,000 
June 5, 2023 ($150,000)   -    150,000 
June 20, 2023 ($50,000) – Funding Commitment   -    50,000 
July 13, 2023 ($50,000) – Funding Commitment   -    50,000 
August 1, 2023 ($190,000) – Funding Commitment   -    190,000 
August 7, 2023 ($50,000) – Funding Commitment   -    42,432 
March 23, 2025 ($500,000)   -    - 
Total notes payable to stockholder (current)  $-   $5,144,460 
SCHEDULE OF FUNDING COMMITMENT

     

   September 30,   December 31, 
   2025   2024 
         
June 20, 2023 ($50,000)  $       -   $50,000 
July 13, 2023 ($50,000)   -    50,000 
August 1, 2023 ($190,000)   -    190,000 
August 7, 2023 ($50,000 original)   -    42,432 
           
Total notes payable to related parties (current)  $-   $332,432 

 

During the nine months ended September 30, 2025, this amount including accrued interest was converted to preferred D shares. The total debt converted was $384,229.

 

March 21, 2025 – $500,000

 

On March 21, 2025, the Company entered into a Loan Authorization and Agreement for a loan of $500,000 from a shareholder, the proceeds of which were to be used for working capital purposes. The loan has an interest rate of 12.5% per annum and is due within 6 months from the date of the agreement. Furthermore, the Company is required to issue 10,000 preferred C shares (issued on April 10, 2025) and 225,000 common stock shares (issued on April 10, 2025) under the agreement. These shares were calculated at fair value at the date of issuance and the Company recorded interest expense of $427,750. This loan balance of $500,000 was converted to preferred stock C during the nine months ended September 30, 2025.